Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE study
2024-515398-90-01Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of flucloxacillin, cefazolin and clindamycin in Staphylococcal bacteremia (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Therapy success at day 180. Started Aug 2024; status: completed.
02
Drugs
flucloxacillincefazolinclindamycin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2024-515398-90-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515398-90-01.